Risk of Systemic Inflammatory Response Syndrome Following Preoperative Glucocorticoids Administration in Patients After Percutaneous Nephrolithotomy: A Retrospective Cohort Study

Jingping Hu, Chaojin Chen, Xiaoyue Li, Xiangyang Zang, Jie Ke, Shaoli Zhou (), Haiyan Mai () and Chulian Gong ()
Additional contact information
Jingping Hu: The Third Affiliated Hospital of Sun Yat-sen University
Chaojin Chen: The Third Affiliated Hospital of Sun Yat-sen University
Xiaoyue Li: The Third Affiliated Hospital of Sun Yat-sen University
Xiangyang Zang: The Third Affiliated Hospital of Sun Yat-sen University
Jie Ke: Guangzhou AID Cloud Technology Co., Ltd
Shaoli Zhou: The Third Affiliated Hospital of Sun Yat-sen University
Haiyan Mai: The Third Affiliated Hospital of Sun Yat-sen University
Chulian Gong: The Third Affiliated Hospital of Sun Yat-sen University

Drug Safety, 2024, vol. 47, issue 5, No 5, 465-474

Abstract: Abstract Introduction Systemic inflammatory response syndrome (SIRS) is one of the most serious complications in patients undergoing percutaneous nephrolithotomy (PCNL). Although glucocorticoids are increasingly used during PCNL, few studies have been concerned about the association between glucocorticoids and postoperative SIRS. The study aims to explore whether preoperative use of glucocorticoids is associated with SIRS after PCNL. Methods A total of 1259 patients who underwent PCNL between January 2015 and April 2021 were enrolled in the retrospective cohort study. Risk factors for post-PCNL SIRS were identified by univariate and multivariate regression analysis. To further explore the association between preoperative administration of glucocorticoids and SIRS, 113 pairs of patients were matched for the confounding factors using propensity score matching (PSM) analysis. The odds ratios (OR) and 95 % confidence intervals (CI) for the above variables were analyzed. Results The incidence of SIRS after PCNL was 9.6 % (121/1259) and the patients who suffered from postoperative SIRS had longer hospital stays and higher hospital costs (all p

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-024-01402-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:47:y:2024:i:5:d:10.1007_s40264-024-01402-y

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-024-01402-y

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().